John McLaren Howard
Biolab Medical Unit 9 Weymouth St. London W1 N 3FF, United Kingdom Drs. Talwar 
and St. JO'Reilly respond:
To the Editor: Dr. McLaren Howard makes an interesting observation relating to the biochemical assessment of thiamin status in people supplemented with the vitamin. In his experience, the indirect measurement of thiamin status using the transketolase (ETK) activation assay is clinically more useful than direct measurement of thiamin diphosphate (TDP) concentrations in red cells in people repleted with thiamin. Unfortunately, we are unable to comment on his observation because no relevant data are presented.
Discrepancies between the ETK activation test and clinical signs of thiamin deficiency have been reported previously, with several studies reporting no relationship between ETK activation results and thiamin intake (1) (2) (3) (4) (5) . These discrepant findings have raised questions about the usefulness of the ETK activation test as a sole indicator of thiamin status.
Because a valid ETK activation response depends on a kinetically normal enzyme (1, 6 ) , certain disease states may affect enzyme cofactor binding and hence the TDP activation effect (6 ) . Because of the potential difficulty in interpretation of ETK activation effect in some disease states and the limitations of enzyme activation tests in general, several authors have suggested the use of more direct measures of thiamin status, such as TDP in whole blood or plasma (4, 6, 7 ) .
We would agree with Dr. McLaren
Howard that further discussion is required on the merits or otherwise of direct and indirect measures of thiamin status in patients repleted with thiamin. Meanwhile, our experience with the HPLC assay suggests that measurement of TDP in red cells is the single most useful biochemical measurement for assessing thiamin status in patients who are at risk of thiamin deficiency.
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Transient Hyperphosphatasemia of Infancy and Childhood: Study of 194 Cases
To the Editor: Transient hyperphosphatasemia of infancy and childhood (TH) is a temporary and isolated increase of serum alkaline phosphatase (ALP; EC 3.1.3.1) activity occurring without obvious cause during the first years of life. Despite several reports about this phenomenon, the origin of TH remains obscure.
Over a period of 8 years (1992-1999), we detected 194 cases of TH in 106 boys and 88 girls. The hyperphosphatasemia was discovered fortuitously during routine investigations in outpatient and inpatient departments of a children's hospital with a capacity of 500 beds. A wide variety of clinical disorders was associated with this condition (gastrointestinal diseases, 24%; respiratory infections, 21%; congenital anomalies and inborn errors of metabolism, 15%; anemia, 10%; malignancies, 7%; neurological disorders, 5%; others, 18%).
We measured total ALP activity using the IFCC-recommended method at 37°C with Elan (Eppendorf) and Cobas Integra (Roche) analyzers. Our reference interval for children was 0.85-6.80 kat/L (51-408 U/L). Adult reference intervals are 0.54 -1.7 kat/L (32-104 U/L) for women and 0.76 -2.0 kat/L (45-122 U/L) for men. In each TH case, we saw the characteristic two-band ALP isoenzyme pattern on Cellogel zonal electrophoresis as described by Stein et al. (1 ) and Behú lová et al. (2 ) .
Although markedly increased ALP activities may occur in TH, frequently only slightly or moderately increased activities are observed, depending on the timing of the blood sample in relation to the natural course of TH. Markedly increased activities, therefore, are not necessary to reach a diagnosis of TH. The peak ALP activity in our series was 2-to 20-fold higher than the pediatric upper reference limit, with the median being a 4-fold increase.
In this series, 49% of cases were detected in the second year of life, and 96% of affected children were younger than 5 years ( Fig. 1 ). We speculate that immaturity of the mechanisms responsible for ALP clearance allows increases of plasma ALP, triggered by an exogenous insult.
We observed a marked seasonal clustering of cases from September to November (43%); the lowest incidence was from January to March (13%). Similar seasonal differences were described previously in a smaller series (3 ) . In addition, we discovered a simultaneous course of TH in three sets of twins and two other sibling pairs (neither parent was affected). "Epidemic" incidence and familial occurrence strongly support a relationship of TH with viral, protozoal, or other infections (4, 5) . On the other hand, these findings might suggest a genetic predisposition for a unique response to any infection.
In our department of clinical biochemistry, ALP isoenzyme electrophoresis has been used for differential diagnosis of TH and organic hyperphosphatasemias. Over the last 8 years, ALP isoenzyme measurements were requested in 562 children under 5 years of age. We detected TH in 187 patients (33%) and hyperphosphatasemia of predominantly bone, intestine, or liver origin in 336 (60%), 21 (4%), and 18 (3%) patients, respectively. To our knowledge, we report the largest series of TH children that has been identified in one hospital. We conclude that TH cannot be regarded as a rare or exceptional syndrome (6 ) and that it belongs among the diagnostic tasks in present-day pediatric chemistry. 
Comparison of Single and Repeat Centrifugation of Blood Specimens Collected in BD Evacuated Blood Collection Tubes Containing a Clot Activator for Cardiac Troponin I Assay on the ACCESS Analyzer
To the Editor: Cardiac troponin I (cTnI) has become a major marker in the diagnosis and monitoring of myocardial damage. On the ACCESS TM analyzer (Beckman Coulter), serum is the biological fluid compatible with both myoglobin and cTnI tests (1 ) . However, residual fibrin (2 ) and microparticles (2 ) have been reported to interfere with one or more cTnI assays. Some of these interferences can be avoided with repeat centrifugation of the sample and/or the use of a clot activator (3 ). The BD Vacutainer TM Hemogard TM Thrombin glass evacuated blood collection tube (BD Thrombin) contains thrombin as a clot activator and may, therefore, obviate the need for repeat centrifugation of samples and the resulting delays in testing.
This open comparative study (without masking of phlebotomists, technicians, or investigators) was performed in the Laboratory of Biochemistry of the University Teaching Hospital Beaujon between August and October 1999. Its objective was to assess whether single centrifugation of blood specimens is adequate for samples collected into BD Thrombin tubes for the assay of cTnI on the ACCESS analyzer.
Patients with chest pain from the emergency department and patients with acute coronary syndrome from the cardiology intensive care unit were included. Samples were drawn in duplicate into BD Thrombin and BD Vacutainer Hemogard SST TM glass tubes (BD SST), the laboratory reference tube, whose sample is routinely centrifuged twice for this assay. Samples were centrifuged at 1300 -2000g for 10 min at 10°C.
The first 64 results (cTnI range, 0 -1.9 g/L) included 10 (16%) above the threshold (0.1 g/L). Results showed a random positive bias of the "BD Thrombin ϩ single centrifuga- 
